Ensartinib is a potent, selective anaplastic lymphoma kinase (ALK) inhibitor utilized in the treatment of ALK-positive non-small cell lung cancer. This category features a comprehensive range of reference… Read more







Ensartinib is a potent, selective anaplastic lymphoma kinase (ALK) inhibitor utilized in the treatment of ALK-positive non-small cell lung cancer. This category features a comprehensive range of reference standards, including pharmacopeial and non-pharmacopeial impurities, synthetic intermediates, degradation products, and stable isotope-labelled compounds. Pharmaceutical laboratories rely on these high-quality standards for rigorous impurity profiling, method development, and validation of analytical procedures such as HPLC and LC-MS. Stable isotope-labelled analogues are specifically essential for accurate quantification and as internal standards in complex quality control matrices. Furthermore, these reference materials support forced degradation studies and the identification of process-related contaminants or N-nitroso variants. By providing structurally characterized compounds, these standards enable compliance with regulatory requirements for safety and efficacy throughout the drug development lifecycle, ensuring precise monitoring of Ensartinib throughout pharmaceutical research and manufacturing.